BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 32609294)

  • 1. Association of End Point Definition and Randomized Clinical Trial Duration in Clinical Trials of Schizophrenia Medications.
    Younis IR; Gopalakrishnan M; Mathis M; Mehta M; Uppoor R; Zhu H; Farchione T
    JAMA Psychiatry; 2020 Oct; 77(10):1064-1071. PubMed ID: 32609294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2012 Jun; 73(6):856-64. PubMed ID: 22687813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.
    Lewis SW; Davies L; Jones PB; Barnes TR; Murray RM; Kerwin R; Taylor D; Hayhurst KP; Markwick A; Lloyd H; Dunn G
    Health Technol Assess; 2006 May; 10(17):iii-iv, ix-xi, 1-165. PubMed ID: 16707074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women: A Randomized Clinical Trial.
    Kulkarni J; Gavrilidis E; Gwini SM; Worsley R; Grigg J; Warren A; Gurvich C; Gilbert H; Berk M; Davis SR
    JAMA Psychiatry; 2016 Sep; 73(9):947-54. PubMed ID: 27438995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Trend of Increasing Placebo Response and Decreasing Treatment Effect in Schizophrenia Trials Continues: An Update From the US Food and Drug Administration.
    Gopalakrishnan M; Zhu H; Farchione TR; Mathis M; Mehta M; Uppoor R; Younis I
    J Clin Psychiatry; 2020 Mar; 81(2):. PubMed ID: 32141721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial.
    Correll CU; Davis RE; Weingart M; Saillard J; O'Gorman C; Kane JM; Lieberman JA; Tamminga CA; Mates S; Vanover KE
    JAMA Psychiatry; 2020 Apr; 77(4):349-358. PubMed ID: 31913424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zuclopenthixol dihydrochloride for schizophrenia.
    Bryan EJ; Purcell MA; Kumar A
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD005474. PubMed ID: 29144549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Tolerability of Adjunctive Intravenous Sodium Nitroprusside Treatment for Outpatients With Schizophrenia: A Randomized Clinical Trial.
    Brown HE; Freudenreich O; Fan X; Heard SO; Goff D; Petrides G; Harrington AL; Kane JM; Judge H; Hoeppner B; Fava M; Perlis RH
    JAMA Psychiatry; 2019 Jul; 76(7):691-699. PubMed ID: 30916714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
    Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S
    JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial.
    Kaul I; Sawchak S; Walling DP; Tamminga CA; Breier A; Zhu H; Miller AC; Paul SM; Brannan SK
    JAMA Psychiatry; 2024 May; ():. PubMed ID: 38691387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?
    Tollefson GD; Andersen SW
    J Clin Psychiatry; 1999; 60 Suppl 5():23-9; discussion 30. PubMed ID: 10192404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modelling and simulation of the Positive and Negative Syndrome Scale (PANSS) time course and dropout hazard in placebo arms of schizophrenia clinical trials.
    Pilla Reddy V; Kozielska M; Johnson M; Suleiman AA; Vermeulen A; Liu J; de Greef R; Groothuis GM; Danhof M; Proost JH
    Clin Pharmacokinet; 2012 Apr; 51(4):261-75. PubMed ID: 22420580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Adjunctive Estradiol on Schizophrenia Among Women of Childbearing Age: A Randomized Clinical Trial.
    Weiser M; Levi L; Zamora D; Biegon A; SanGiovanni JP; Davidson M; Burshtein S; Gonen I; Radu P; Slobozean Pavalache K; Nastas I; Hemi R; Ryan T; Davis JM
    JAMA Psychiatry; 2019 Oct; 76(10):1009-1017. PubMed ID: 31365044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia.
    Brannan SK; Sawchak S; Miller AC; Lieberman JA; Paul SM; Breier A
    N Engl J Med; 2021 Feb; 384(8):717-726. PubMed ID: 33626254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia.
    Ruberg SJ; Chen L; Stauffer V; Ascher-Svanum H; Kollack-Walker S; Conley RR; Kane J; Kinon BJ
    BMC Psychiatry; 2011 Feb; 11():23. PubMed ID: 21306626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early Placebo Improvement Is a Marker for Subsequent Placebo Response in Long-Acting Injectable Antipsychotic Trials for Schizophrenia: Combined Analysis of 4 RCTs.
    Kumagai F; Suzuki T; Fleischhacker WW; Yasui-Furukori N; Mimura M; Uchida H
    J Clin Psychiatry; 2018 Dec; 80(1):. PubMed ID: 30549487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.